The Potential of Trodelvy® for Patients with HR+/HER2- Metastatic Breast Cancer Patients Treated with Trodelvy®
Sacituzumab Govitecan Is a First-in-Class Trop-2‒Directed Antibody-Drug Conjugate. In this MEDtalk Professor of Medicine Hope S. Rugo, MD, University of California San Francisco, gives her perspective of Sacituzumab Govitecan for patients with HR+/HER2- Metastatic Breast Cancer.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
